Ipsen/Genfit eye June FDA verdict for liver drug elafibranor

The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a date of 10th June to deliver a decision.